Target organ involvement in hypertension: A realistic promise of prevention and reversal

Medical Clinics of North America

Volumn 88, Issue 1, 2004, Pages 209-221

  Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGING; ANTIHYPERTENSIVE THERAPY; APOPTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY HEMODYNAMICS; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0842264853     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(03)00117-2     Document Type: Review

References (70)

1. Joint National Committee on Prevention. Detection, evaluation, and treatment of high blood pressure. The Sixth Report of the Joint National Committee (JNC-VI) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446.
2. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7). JAMA. 289:2003;2560-2572.
3. Collins C., Peto R., MacMahon S., Hebert P., Fiebach N.H., Eberlein K.A., et al. Blood pressure, stroke and coronary heart disease Part II. Short-term reductions in blood pressure overview of randomized drug trials in their epidemiological context . Lancet. 335:1990;827-838.
4. Thijs L., Fagard R., Lijuen F., Staessen J., Van Hoof R., Amery A. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 10:1992;1103-1109.
5. Chalmers J., et al. International Society of Hypertension Writing Group (WHO-ISH). International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens. 21:2003;651-663.
6. Vasan R.S., Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 156:1996;1789-1796.
7. Vasan R.S., Benjamin E.J., Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 26:1995;156.
8. McKee P.A., Castelli W.P., McNamara O.M., Kannel W.B. The natural history of congestive heart failure: the Framingham Heart Study. N Engl J Med. 285:1971;1441-1446.
9. Frohlich E.D. Risk mechanisms in hypertensive heart disease. Hypertension. 34:1999;782-789.
10. Slama M., Susic D., Varagic J., Frohlich E.D. Diastolic dysfunction in hypertension. Curr Opin Cardiol. 17:2002;368-373.
11. Nixenberg A., Antony I. Epicardial coronary arteries are not adequately sized in hypertensive patients. J Am Coll Cardiol. 27:1996;1115-1123.
12. Weber K.T., Sun Y., Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 23:1994;869-877.
13. Weber K.T. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 96:1997;4065-4082.
14. Marcus M.L., Duty D.B., Hiratska L.F., Wright C.B., Eustham C.L. Decreased coronary reserve: a mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N Engl J Med. 307:1982;1362-1367.
15. Opherk D., Nall G., Zebe H., Schwarz F., Weihe E., Manthy E., et al. Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 69:1984;1-7.
16. Brash J.E. Jr., Cannon R.O., Schenke W.H., Bonow R.O., Leon M.B., Maron B.J., et al. Angina due to coronary microvascular disease in hypertension without left ventricular hypertrophy. N Engl J Med. 319:1988;1302-1307.
17. Houghton J.L., Frank M.J., Carr A.A., von Dohlen T.W., Prisant L.M. Relations among impaired coronary flow reserve: left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without destructive coronary artery disease. J Am Coll Cardiol. 15:1990;43-51.
18. Scheler S., Wolfgang M., Strauer B.E. Mechanisms of angina pectoris with essential hypertension and normal epicardial arteries by arteriogram. Am J Cardiol. 73:1994;478-482.
19. Treasure C.B., Klein J.L., Vita J.A., Manoukian S.V., Renwich G.H., Selwin A.P., et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 87:1993;86-93.
20. Lüscher T.F. The endothelium in hypertension: bystander, target or mediator? J Hypertens. 12:1994;105-116.
21. Küng C.F., Lüscher T.F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 25:1995;194-200.
22. Gauthier-Rein K.M., Rusch N.J. Distinct endothelial impairment in coronary microvessels from hypertensive Dahl rats. Hypertension. 31:1998;328-334.
23. Zeiher A.M., Drexler H., Saurbier B., Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 92:1993;652-662.
24. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet. 338:1991;1546-1550.
25. Bøttchen M., Bøtker H.E., Sonne H., Nielsen T.T., Czernin J. Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with Syndrome X. Circulation. 99:1999;1795-1801.
26. Diez J., Querejeta R., Lopez B., Gonzalez A., Larman M., Martinez Ubago J.L. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 105:2002;2512-2517.
27. Gonzalez A., Lopez B., Ravassa S., Querejeta R., Larman M., Diez J., et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension. 39:2002;75-80.
28. Fortuno M.A., Gonzalez A., Ravassa S., Lopez B., Diez J. Clinical implications of apoptosis in hypertensive heart disease. Am J Physiol. 2003;. in press.
29. Frohlich E.D., Apstein C., Chobanian A.V., Devereux R.B., Dustan H.P., Dzau V., et al. The heart in hypertension. N Engl J Med. 327:1992;998-1008.
30. Kannel W.B., Dawber T.R., Kagan A., Revorskie N., Sacks J. Factors of risk in the development of coronary heart disease: six year follow up experience. The Framingham Study. Ann Intern Med. 55:1961;33-56.
31. Kannel W.B., Gordon T., Offut D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. Ann Intern Med. 71:1969;99-105.
32. Frohlich E.D. Is reversal of left ventricular hypertrophy in hypertension beneficial? Hypertension. 18:1991;133-138.
33. Susic D., Nunez E., Hosoya H., Frohlich E.D. Coronary hemodynamics in aging spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. J Hypertens. 16:1998;231-237.
34. Rossi M.A. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 16:1998;1031-1041.
35. Folkow B. Cardiovascular structural adaptation: Its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med. 48:1975;205s-214s.
36. Nishiyama K., Nishiyama A., Frohlich E.D. Regional blood flow in normotensive and spontaneously hypertensive rats. Am J Physiol. 230:1976;691-698.
37. Susic D., Frohlich E.D. Pharmacologic agents on cardiovascular mass and coronary hemodynamics in aging spontaneously hypertensive rats. J Hypertens. 17:1999;1-7.
38. Schwartzkopff B., Brehm M., Mundhenke M., Strauer B.E. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 36:2000;220-225.
39. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 102:2000;1388-1393.
40. Frohlich E.D., Sasaki O. Dissociation of changes in cardiovascular mass and performance with angiotensin converting enzyme inhibitors in Wistar-Kyoto and spontaneously hypertensive rats. J Am Coll Cardiol. 16:1990;1492-1499.
41. Nunez E., Hosoya K., Susic D., Frohlich E.D. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension. 29:1997;519-524.
42. Varagic J., Susic D., Frohlich E.D. Coronary hemodynamic and ventricular responses to AT1 receptor inhibition in SHR interaction with AT2 receptors. Hypertension. 37:2001;1399-1403.
43. Frohlich E.D., Sasaki O., Chien Y., Arita M. Changes in cardiovascular mass, left ventricular pumping ability, and aortic distensibility after calcium antagonists in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens. 10:1992;1369-1378.
44. Arita M., Horinaka S., Frohlich E.D. Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens. 11:1993;951-959.
45. Arita M., Horinaka S., Komatsu K., Frohlich E.D. Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes. J Hypertens. 11:1993;S354-S355.
46. Aristizabal D., Messerli F.H., Frohlich E.D. Disparate structural effects of left and right ventricles by angiotensin converting enzyme inhibitors and calcium antagonists. Am J Cardiol. 73:1994;483-487.
47. Susic D., Francischetti A., Frohlich E.D. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension. 33:1999;451-455.
48. Ono H., Ono Y., Frohlich E.D. L-Arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats. J Hypertens. 17:1999;121-128.
49. Susic D., Varagic J., Frohlich E.D. Isolated systolic hypertension in elderly WKY's reversed with L-arginine and ACE inhibition. Hypertension. 38:2001;1422-1426.
50. US Renal Data Systems. 1995 Annual Data Report. National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, III: incidence and causes of treated ESRD . Am J Kidney Dis. 26:1995;S39-S50.
51. Hostetter T.H., Olson J.L., Rennke H.G., Venkatachalam M.A., Brenner B.M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 241:1981;F85-F93.
52. Brenner B.M., Meyer T.W., Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the tale of hemodynamically mediated glomerular disease in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 307:1982;652-659.
53. UKPDS Group. UK Prospective Diabetes Study 38: tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 317:1998;703-713.
54. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 320:1993;1456-1462.
55. UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDA 39. BMJ. 317:1998;713-720.
56. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 353:1999;611-616.
57. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
58. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
59. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345:2001;870-878.
60. Agodoa L.Y., Appel L., Bakris G.L., Beck G., Bourgoignie J., Briggs J.P., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 285:2001;2719-2728.
61. Frohlich ED, Sowers JR. Management of diabetic and hypertensive cardiovascular disease. Curr Hypertens Rep, in press.
62. Komatsu K., Frohlich E.D., Ono H., Ono Y., Numabe A., Willis G.W. Glomerular dynamics and morphology of aged SHR: effects of angiotensin converting enzyme inhibitor. Hypertension. 25:1995;207-213.
63. Ono H., Ono Y., Frohlich E.D. Nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension. 26:1995;249-255.
64. Uchino K., Frohlich E.D., Nishikimi T., Isshiki T., Kardon M.B. Spontaneously hypertensive rats demonstrate increased renal vascular alpha 1 adrenergic receptor responsiveness. Am J Physiol. 260:1991;R889-R893.
65. Uchino K., Nishikimi T., Frohlich E.D. Alpha-1 adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistance in SHR. Am J Physiol. 261:1991;R576-R580.
66. Ono H., Ono Y., Frohlich E.D. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension. 27:1996;176-183.
67. Ono Y., Ono H., Frohlich E.D. Hydrochlorothiazide exacerbates nitric oxide blockades nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens. 14:1996;823-828.
68. Francischetti A., Ono H., Frohlich E.D. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension. 31:1998;795-801.
69. Nakamura Y., Ono H., Zhou X., Frohlich E.D. Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in L-NAME/SHR rats. Hypertension. 37:2001;1262-1267.
70. Nakamura Y., Ono H., Frohlich E.D. Differential effect of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension. 34:1999;273-278.